Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Дата публикации: 21-07-2026 20:07:07

FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE) July 21, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development	0	17.54	24-07-2026
2	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
3	First Once-Weekly Oral HIV Treatment Demonstrates Safety and Efficacy	0	14.22	07-08-2026
4	Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)	0	18.81	22-06-2026
5	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet	0	9.57	29-07-2026
6	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
7	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
8	ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia	0	12.15	06-10-2026
9	Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma	0	12.59	10-07-2026
10	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	0	12.36	14-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.6. Источник: www.drugs.com.